Your browser doesn't support javascript.
loading
The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review.
Kratz, Jeremy David; Klein, Alyssa Barchet; Gray, Courtney Beth; Märten, Angela; Vilu, Hanna-Liisa; Knight, Jennifer Francesca; Kumichel, Alexandra; Ueno, Makoto.
Afiliación
  • Kratz JD; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. jdkratz@medicine.wisc.edu.
  • Klein AB; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. jdkratz@medicine.wisc.edu.
  • Gray CB; William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. jdkratz@medicine.wisc.edu.
  • Märten A; Wi Institute Medical Research, 1111 Highland Ave Room 2784, Madison, WI, 53705-2275, USA. jdkratz@medicine.wisc.edu.
  • Vilu HL; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Knight JF; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Kumichel A; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Ueno M; Evidera Ltd, London, UK.
Target Oncol ; 2024 Sep 20.
Article en En | MEDLINE | ID: mdl-39302603
ABSTRACT
Biliary tract cancer (BTC) is a rare and aggressive malignancy that is anatomically classified as gallbladder cancer (GBC), extra- and intra-hepatic cholangiocarcinoma (eCCA and iCCA) and ampullary cancer (AC). BTC is often diagnosed at an advanced stage when treatment options are limited and patients have a poor prognosis, so the identification of new drug targets is of critical importance. BTC is molecularly diverse and harbours different therapeutically actionable biomarkers, including mouse double minute 2 homolog (MDM2), which is currently being investigated as a drug target. The aim of this targeted review was to evaluate and synthesise evidence on the epidemiology of BTC and its subtypes in different geographic regions and on the frequency of MDM2 amplifications in BTC tumours. Epidemiological studies (N = 33) consistently demonstrated high incidence rates in South and Central Asia for BTC overall (up to 9.00/100,000) and for all subtypes, with much lower rates in Europe and the US. Among the different types of BTC, the highest global incidence was observed for CCA, mainly driven by iCCA (1.4/100,000), followed by GBC (1.2/100,000) and AC (0.18-0.93 per 100,000). Studies of MDM2 in BTC (N = 19) demonstrated variable frequency of MDM2 amplification according to subtype, with consistently high MDM2 amplification rates in GBC (up to 17.5%), and lower rates in CCA (up to 4.4%). The results from this literature review highlight the geographic heterogeneity of BTC and the need for standardised clinicopathologic assessment and reporting to allow cross-study comparisons.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Francia